SARS‐CoV‐2 infection increases tacrolimus concentrations in solid‐organ transplant recipients

Calcineurin inhibitors (CNIs) are narrow therapeutic index medications, with drug concentrations altered by factors such as drug-drug interactions, clinical symptoms including diarrhea, and hepatic dysfunction. Supratherapeutic CNI concentrations can produce a myriad of toxicities, the most worrisome of which are renal injury and seizures. New York State was the epicenter of COVID-19 infection in the United States.1 The extent of tacrolimus...